Search Results - "Owens, Charlotte D."

Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids by Schlaff, William D, Ackerman, Ronald T, Al-Hendy, Ayman, Archer, David F, Barnhart, Kurt T, Bradley, Linda D, Carr, Bruce R, Feinberg, Eve C, Hurtado, Sandra M, Kim, JinHee, Liu, Ran, Mabey, R. Garn, Owens, Charlotte D, Poindexter, Alfred, Puscheck, Elizabeth E, Rodriguez-Ginorio, Henry, Simon, James A, Soliman, Ahmed M, Stewart, Elizabeth A, Watts, Nelson B, Muneyyirci-Delale, Ozgul

“…In two identical, double-blind, randomized, 6-month phase 3 trials, elagolix (an oral gonadotropin-releasing hormone antagonist), administered with hormonal…”
Get full text

Elagolix for Fibroid-Associated Heavy Menstrual Bleeding. Reply by Schlaff, William D, Owens, Charlotte D, Muneyyirci-Delale, Ozgul

Get full text

Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas by Simon, James A., Al-Hendy, Ayman, Archer, David F., Barnhart, Kurt T., Bradley, Linda D., Carr, Bruce R., Dayspring, Thomas, Feinberg, Eve C., Gillispie, Veronica, Hurtado, Sandra, Kim, JinHee, Liu, Ran, Owens, Charlotte D., Muneyyirci-Delale, Ozgul, Wang, Alice, Watts, Nelson B., Schlaff, William D.

“…OBJECTIVE:To investigate the safety and efficacy of elagolix, an oral gonadotropin-releasing hormone antagonist, with hormonal add-back therapy for up to 12…”
Get full text

Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial by Carr, Bruce R, Stewart, Elizabeth A, Archer, David F, Al-Hendy, Ayman, Bradley, Linda, Watts, Nelson B, Diamond, Michael P, Gao, Jingjing, Owens, Charlotte D, Chwalisz, Kristof, Duan, W Rachel, Soliman, Ahmed M, Dufek, Matthew B, Simon, James A

“…OBJECTIVE:To evaluate elagolix, an oral gonadotropin-releasing hormone receptor antagonist, alone or with add-back therapy, in premenopausal women with heavy…”
Get full text

Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids by Al-Hendy, Ayman, Bradley, Linda, Owens, Charlotte D., Wang, Hui, Barnhart, Kurt T., Feinberg, Eve, Schlaff, William D., Puscheck, Elizabeth E., Wang, Alice, Gillispie, Veronica, Hurtado, Sandra, Muneyyirci-Delale, Ozgul, Archer, David F., Carr, Bruce R., Simon, James A., Stewart, Elizabeth A.

“…Uterine fibroids are one of the most common neoplasms found among women globally, with a prevalence of approximately 11 million women in the United States…”
Get full text

Elagolix Reduced Heavy Menstrual Bleeding With Uterine Fibroids: Primary, 6-Month, Phase 3 Results [11OP] by Schlaff, William, Al-Hendy, Ayman, Barnhart, Kurt, Owens, Charlotte D, Liu, Ran, Muneyyirci-Delale, Ozgul

“…INTRODUCTION:The objective was to evaluate the efficacy and safety of elagolix, an oral, non-peptide, gonadotropin-releasing hormone antagonist, with add-back…”
Get full text

Impact of uterine fibroid symptoms on health-related quality of life of US women: evidence from a cross-sectional survey by Soliman, Ahmed M., Margolis, Mary Kay, Castelli-Haley, Jane, Fuldeore, Mahesh J., Owens, Charlotte D., Coyne, Karin S.

“…Background: Uterine fibroids (UF) are associated with significant health-related quality of life (HRQL) impact. This study examined the impact of UF symptoms…”
Get full text

Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids by Stewart, Elizabeth A, Archer, David F, Owens, Charlotte D, Barnhart, Kurt T, Bradley, Linda D, Feinberg, Eve C, Gillispie-Bell, Veronica, Imudia, Anthony N, Liu, Ran, Kim, Jin Hee, Al-Hendy, Ayman

“…To assess outcomes of women with uterine fibroids (UFs) and heavy menstrual bleeding (HMB) treated with 300 mg elagolix twice daily plus add-back therapy (E2 1…”
Get more information

Examining the Relationship Between Symptomatic Burden and Self-reported Productivity Losses Among Patients With Uterine Fibroids in the United States by Soliman, Ahmed M., Anand, Savita Bakhshi, Coyne, Karin S., Castelli-Haley, Jane, Snabes, Michael, Owens, Charlotte D.

“…OBJECTIVE:To evaluate the impact of uterine fibroid symptoms on employment and household productivity. METHODS:An online survey of US women between 18 and 54…”
Get full text

Elagolix Treatment in Women With Uterine Fibroids: Secondary, 6-Month, Phase 3 Efficacy Results [11J] by Bradley, Linda D, Feinberg, Eve C, Liu, Ran, Owens, Charlotte D, Rodriguez-Ginorio, Henry, Simon, James A

“…INTRODUCTION:Objective was to evaluate the effect of elagolix with add-back, as compared with placebo, on menstrual blood loss (MBL), suppression of bleeding,…”
Get full text

Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis by Muneyyirci-Delale, Ozgul, Archer, David F., Owens, Charlotte D., Barnhart, Kurt T., Bradley, Linda D., Feinberg, Eve, Gillispie, Veronica, Hurtado, Sandra, Kim, Jin Hee, Wang, Alice, Wang, Hui, Stewart, Elizabeth A.

“…To determine if coexisting adenomyosis limits the efficacy of elagolix, an oral gonadotropin-releasing hormone antagonist, with hormonal add-back therapy in…”
Get full text

Elagolix Reduces Productivity Losses in Uterine Fibroids Patients With Heavy Menstrual Bleeding [33G] by Diamond, Michael, Soliman, Ahmed M., Gao, Jingjing, Owens, Charlotte D.

“…INTRODUCTION: This study assessed the impact of elagolix, an oral gonadotropin-releasing hormone antagonist, on workplace productivity in uterine fibroids (UF)…”
Get full text

Elagolix for Fibroid-Associated Heavy Menstrual Bleeding by Schiffman, Marc, Lamparello, Nicole A, Schlaff, William D, Owens, Charlotte D, Muneyyirci-Delale, Ozgul

“…To the Editor: Schlaff et al. (Jan. 23 issue) 1 discuss options for the management of uterine fibroids, mentioning a variety of interventional therapies and…”
Get full text

Phase 3 trial results: efficacy and safety of elagolix in a subset of women with uterine fibroids and adenomyosis by Muneyyirci-Delale, Ozgul, Archer, David F., Jeannie Kim, Jin Hee, Liu, Ran, Owens, Charlotte D., Puscheck, Elizabeth E.

Get full text

Endometrial Evaluation in Elagolix-Treated Women With Uterine Fibroids and Heavy Menstrual Bleeding [25G] by Carr, Bruce R., Bradley, Linda D., Owens, Charlotte D., Gao, Jingjing, Chwalisz, Kristof, Simon, James A.

“…INTRODUCTION: Elagolix, an oral gonadotropin-releasing hormone antagonist, with and without add-back therapy, was evaluated in premenopausal women with heavy…”
Get full text

Effect of fibroid location and size on efficacy of elagolix: results from phase 3 clinical trials by Al-Hendy, Ayman, Simon, James, Hurtado, Sandra M., Bradley, Linda D., Owens, Charlotte D., Liu, Ran, Barnhart, Kurt T., Gillispie, Veronica

Get full text

Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas by Simon, James A., Al-Hendy, Ayman, Archer, David F., Barnhart, Kurt T., Bradley, Linda D., Carr, Bruce R., Dayspring, Thomas, Feinberg, Eve C., Gillispie, Veronica, Hurtado, Sandra, Kim, JinHee, Liu, Ran, Owens, Charlotte D., Muneyyirci-Delale, Ozgul, Wang, Alice, Watts, Nelson B., Schlaff, William D.

“…(Abstracted from Obstet Gynecol 2020;135:1313–1326) Uterine leiomyomas affect up to 80% of reproductive-age women and are the most common benign neoplasm of…”
Get full text